Serum free light chains: diagnostic and prognostic value in multiple myeloma

Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with se...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 47; no. 9; pp. 1101 - 1107
Main Authors Sthaneshwar, Pavai, Nadarajan, Veerasekaran, Maniam, Jayaranee A.S., Nordin, Nani, Gin Gin, Gan
Format Journal Article
LanguageEnglish
Published Berlin Walter de Gruyter 01.09.2009
De Gruyter
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda (κ/λ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for κ and λ secretors, respectively, for assessing survival. Survival was 30 months in patients with the κ/λ ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the κ/λ ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009;47:1101–7.
AbstractList Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda ( Kappa / lambda ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for Kappa and lambda secretors, respectively, for assessing survival. Survival was 30months in patients with the Kappa / lambda ratio of >57.5 and <0.04 compared to 47months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the Kappa / lambda ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009; 47:1101-7.
Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. We measured FLC concentrations and calculated the kappa/lambda (kappa/lambda) FLC ratios for three groups (control, polyclonal gammopathy and MM). The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for kappa and lambda secretors, respectively, for assessing survival. Survival was 30 months in patients with the kappa/lambda ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the kappa/lambda ratio provides prognostic information in these same patients.
Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda (κ/λ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for κ and λ secretors, respectively, for assessing survival. Survival was 30 months in patients with the κ/λ ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the κ/λ ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009;47:1101–7.
BACKGROUNDMeasurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM.METHODSWe measured FLC concentrations and calculated the kappa/lambda (kappa/lambda) FLC ratios for three groups (control, polyclonal gammopathy and MM).RESULTSThe FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for kappa and lambda secretors, respectively, for assessing survival. Survival was 30 months in patients with the kappa/lambda ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011).CONCLUSIONSDespite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the kappa/lambda ratio provides prognostic information in these same patients.
Author Nadarajan, Veerasekaran
Gin Gin, Gan
Nordin, Nani
Sthaneshwar, Pavai
Maniam, Jayaranee A.S.
Author_xml – sequence: 1
  givenname: Pavai
  surname: Sthaneshwar
  fullname: Sthaneshwar, Pavai
  organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya
– sequence: 2
  givenname: Veerasekaran
  surname: Nadarajan
  fullname: Nadarajan, Veerasekaran
  organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya
– sequence: 3
  givenname: Jayaranee A.S.
  surname: Maniam
  fullname: Maniam, Jayaranee A.S.
  organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya
– sequence: 4
  givenname: Nani
  surname: Nordin
  fullname: Nordin, Nani
  organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya
– sequence: 5
  givenname: Gan
  surname: Gin Gin
  fullname: Gin Gin, Gan
  organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21964749$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19728852$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1P3DAURa2KqsC0y24rb1pWGfwZJ93RAUrLINQCm26sF-cF3DrJYCcI_j2ZMoVdF5b95KP7rs4u2er6Dgl5z9mca673F4vl2VwwVs5Fzl6RHa6kyZSUfOvvW2V5Lvg22U3pN2Nca2XekG1eGlEUWuyQ5QXGsaVNRKTBX98M1N2A79JnWnu47vo0eEehq-kq9v_GOwgjUt_RdgyDXwWk7QOGvoW35HUDIeG7zT0jV8dHl4uTbHn-9dviYJk5JdmQibyosK6qymkuC1BTS6VBlUJIJusKhCmgRFZI5go00jjOcgam0abmtQAtZ2TvKXcqdTtiGmzrk8MQoMN-TNYoXTKtBZvIT_8lc5NLqaYzI9kT6GKfUsTGrqJvIT5YzuxatF2LtmvRdhI98R82wWPVYv1Cb8xOwMcNAMlBaCJ0zqdnTvAyV0aVL4t9GvD--R_in6mcNNr-uFT2-y_Df56cHtov8hHvi5Vs
CitedBy_id crossref_primary_10_1007_s11899_016_0307_4
crossref_primary_10_1016_j_cca_2013_08_018
crossref_primary_10_17650_1818_8346_2020_15_3_38_50
crossref_primary_10_3109_10428194_2012_704033
crossref_primary_10_1371_journal_pone_0166841
crossref_primary_10_1515_CCLM_2010_283
crossref_primary_10_1515_CCLM_2011_019
crossref_primary_10_1007_s13631_016_0130_x
crossref_primary_10_1177_0004563213518758
crossref_primary_10_1515_CCLM_2009_265
Cites_doi 10.1046/j.1365-2141.1997.8672495.x
10.1093/clinchem/47.4.673
10.1046/j.1365-2141.2003.04355.x
10.1182/blood.V97.9.2900
10.1111/j.1365-2141.2008.07079.x
10.2307/2281868
10.1016/j.clinbiochem.2006.11.011
10.1007/s00277-005-1047-z
10.1182/blood.V63.2.468.468
10.1111/j.1365-2141.2004.05045.x
10.1373/49.8.1252
10.1038/leu.2008.171
10.1016/0002-9343(67)90074-5
10.1111/j.1365-2141.1990.tb07790.x
10.1373/clinchem.2008.106153
10.1038/leu.2008.307
10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
10.1182/blood-2007-01-067728
10.1016/S0140-6736(03)12457-9
10.3346/jkms.2006.21.4.639
10.1111/j.1365-2141.2007.06561.x
10.1093/clinchem/48.9.1437
10.1182/blood.V97.6.1566
10.1309/AJCPR2M4EUYNHLGM
10.1016/S0009-9120(02)00386-7
ContentType Journal Article
Copyright 2009 INIST-CNRS
Copyright_xml – notice: 2009 INIST-CNRS
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7T5
H94
DOI 10.1515/CCLM.2009.260
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1437-4331
EndPage 1107
ExternalDocumentID 10_1515_CCLM_2009_260
19728852
21964749
ark_67375_QT4_JZ71RHKD_B
Genre Evaluation Studies
Journal Article
GroupedDBID ---
-~0
0R~
0~D
1CY
29B
354
36B
4.4
53G
5GY
5RE
9-L
AAAEU
AABBZ
AAFNC
AAFPC
AAGVJ
AAILP
AALGR
AAONY
AAOQK
AAOTM
AAOWA
AAPJK
AAQCX
AASQH
AAWFC
AAXCG
ABAOT
ABAQN
ABFKT
ABFQV
ABIQR
ABJNI
ABLJU
ABMIY
ABPLS
ABRDF
ABRQL
ABUBZ
ABUVI
ABVMU
ABWLS
ABXMZ
ABYBW
ACEFL
ACGFS
ACIWK
ACMKP
ACPMA
ACPRK
ACXLN
ACZBO
ADALX
ADDWE
ADEQT
ADGQD
ADGYE
ADOZN
ADUQZ
AEDGQ
AEGVQ
AEICA
AEJTT
AEKEB
AENEX
AEQDQ
AERZL
AEXIE
AFAUI
AFBAA
AFBQV
AFCXV
AFGDO
AFGNR
AFQUK
AFRAH
AFYRI
AGBEV
AGGNV
AHOVO
AHVWV
AHXUK
AIERV
AIKXB
AJATJ
AJHHK
AKXKS
ALMA_UNASSIGNED_HOLDINGS
ALUKF
ALYBR
AMAVY
ASPBG
ASYPN
AVWKF
AZFZN
AZMOX
BAKPI
BBCWN
BCIFA
BSCLL
BWHEM
CAG
CGQUA
COF
CS3
DA2
DBYYV
DU5
EJD
EMOBN
F5P
FSTRU
HZ~
IL9
IY9
KDIRW
N9A
O9-
OBC
OBS
OEB
OES
OHH
OVD
P2P
PQQKQ
QD8
RDG
SA.
SLJYH
TEORI
UK5
WTRAM
~Z8
.55
.GJ
AAEMA
AAUGY
AAZFL
ABPTK
ACTFP
AI.
AIGSN
DSRVY
EBS
EYIDJ
IQODW
ITC
VH1
X7M
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7T5
H94
ID FETCH-LOGICAL-c430t-268bedbbbc5138a443445a4922303dba278a9e0830c8e737c1060a7f57d1d2a53
ISSN 1434-6621
IngestDate Fri Oct 25 09:09:34 EDT 2024
Fri Oct 25 02:58:22 EDT 2024
Thu Sep 12 18:43:50 EDT 2024
Sat Sep 28 07:55:52 EDT 2024
Sun Oct 22 16:07:28 EDT 2023
Wed Oct 30 09:48:33 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords microglobulin
Immunopathology
multiple myeloma
Prognosis
Free form
serum electrophoresis
Malignant hemopathy
Light peptide chain
Myeloma
Medicine
β
serum free light chains
Immunoglobulinopathy
Lymphoproliferative syndrome
Clinical biology
Electrophoresis
Serum
Diagnosis
Cancer
β2-Microglobulin
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c430t-268bedbbbc5138a443445a4922303dba278a9e0830c8e737c1060a7f57d1d2a53
Notes ark:/67375/QT4-JZ71RHKD-B
ArticleID:cclm.2009.260
istex:F6A6197DF06313C6FC7852ABEF608A9B7E4A1159
cclm.2009.260.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink https://edoc.hu-berlin.de/bitstream/18452/11422/1/cclm.2009.260.pdf
PMID 19728852
PQID 67633463
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_745905520
proquest_miscellaneous_67633463
crossref_primary_10_1515_CCLM_2009_260
pubmed_primary_19728852
pascalfrancis_primary_21964749
istex_primary_ark_67375_QT4_JZ71RHKD_B
PublicationCentury 2000
PublicationDate 2009-09-01
PublicationDateYYYYMMDD 2009-09-01
PublicationDate_xml – month: 09
  year: 2009
  text: 2009-09-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
PublicationTitle Clinical chemistry and laboratory medicine
PublicationTitleAlternate Clin Chem Lab Med
PublicationYear 2009
Publisher Walter de Gruyter
De Gruyter
Publisher_xml – name: Walter de Gruyter
– name: De Gruyter
References p_23
p_24
p_25
p_26
Katzmann JA (p_4) 2002; 48
Bataille R (p_22) 1984; 63
p_20
p_21
p_16
p_17
p_2
p_18
p_19
p_12
p_3
p_13
p_14
p_5
p_15
p_8
p_7
p_9
Bradwell AR (p_6) 2001; 47
p_10
p_11
Merlini G (p_1) 1995; 8
References_xml – ident: p_23
  doi: 10.1046/j.1365-2141.1997.8672495.x
– volume: 47
  start-page: 673
  year: 2001
  ident: p_6
  publication-title: Clin Chem
  doi: 10.1093/clinchem/47.4.673
  contributor:
    fullname: Bradwell AR
– ident: p_2
  doi: 10.1046/j.1365-2141.2003.04355.x
– ident: p_10
  doi: 10.1182/blood.V97.9.2900
– ident: p_11
  doi: 10.1111/j.1365-2141.2008.07079.x
– ident: p_8
  doi: 10.2307/2281868
– ident: p_9
  doi: 10.1016/j.clinbiochem.2006.11.011
– volume: 8
  start-page: 173
  year: 1995
  ident: p_1
  publication-title: Cancer J
  contributor:
    fullname: Merlini G
– ident: p_15
  doi: 10.1007/s00277-005-1047-z
– volume: 63
  start-page: 468
  year: 1984
  ident: p_22
  publication-title: Blood
  doi: 10.1182/blood.V63.2.468.468
  contributor:
    fullname: Bataille R
– ident: p_12
  doi: 10.1111/j.1365-2141.2004.05045.x
– ident: p_13
  doi: 10.1373/49.8.1252
– ident: p_7
  doi: 10.1038/leu.2008.171
– ident: p_17
  doi: 10.1016/0002-9343(67)90074-5
– ident: p_21
  doi: 10.1111/j.1365-2141.1990.tb07790.x
– ident: p_16
  doi: 10.1373/clinchem.2008.106153
– ident: p_26
  doi: 10.1038/leu.2008.307
– ident: p_18
  doi: 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
– ident: p_24
  doi: 10.1182/blood-2007-01-067728
– ident: p_3
  doi: 10.1016/S0140-6736(03)12457-9
– ident: p_19
  doi: 10.3346/jkms.2006.21.4.639
– ident: p_25
  doi: 10.1111/j.1365-2141.2007.06561.x
– volume: 48
  start-page: 1437
  year: 2002
  ident: p_4
  publication-title: Clin Chem
  doi: 10.1093/clinchem/48.9.1437
  contributor:
    fullname: Katzmann JA
– ident: p_20
  doi: 10.1182/blood.V97.6.1566
– ident: p_14
  doi: 10.1309/AJCPR2M4EUYNHLGM
– ident: p_5
  doi: 10.1016/S0009-9120(02)00386-7
SSID ssj0015547
Score 2.03732
Snippet Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell...
Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim...
BACKGROUNDMeasurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias....
SourceID proquest
crossref
pubmed
pascalfrancis
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 1101
SubjectTerms Aged
Biological and medical sciences
Blood Protein Electrophoresis - methods
Female
General aspects
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulin kappa-Chains - blood
Immunoglobulin lambda-Chains - blood
Immunoglobulinopathies
Immunopathology
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - mortality
Prognosis
Sensitivity and Specificity
serum electrophoresis
serum free light chains
Survival Analysis
β2-microglobulin
Title Serum free light chains: diagnostic and prognostic value in multiple myeloma
URI https://api.istex.fr/ark:/67375/QT4-JZ71RHKD-B/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/19728852
https://search.proquest.com/docview/67633463
https://search.proquest.com/docview/745905520
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKKgEvCMatXIYfEC9TIYntOOGtK4NqrBOXbpp4iezE0bqt6ZS2jPHrOb4kaadVAl6qNvf6-3xyjn3OZ4ReC-WB20BlV0roblRBnBLxzOvm4JxmxGfCi3U18vAgHBzSvWN23GpdLleXzOXb9PeNdSX_gypsA1x1lew_IFtfFDbAd8AXPgFh-PwrjKGjLybbeanU9rkOsnUZrx4_hig_syl0lRyrTsNyP7W8t1EKqXMJJ1fqfOrscyVaUBVMptWCcOYyjjJ6Xv76pPx3PQavZieXNmP7i_gpxvVIs8hEKU7tWOuRUiW8Os9gS03MoSjGrl5bXOkd8I96zajsAUTIVusAXgbjlYGKJhML3jPWuFLCmwotZ32t3qZjWbxkSsEv8W-08czIYfT7-0MrNxrYBQmW8L6YGMD1impRZAVyr4lqV7tuoXYAFgpMY7v3aWf3qJ6AAi-LO0lWuN-7lbsZoVl7_oo309Yd85fOrhUzQCi3K6OsD12MCzO6j-652AP3LJEeoJYqNtGdfoXwJro9dKA-RPuGW1hzCxtuYcut97hhFgZK4IZZ2DALjwtcMQs7Zj1Chx93R_1B16280U0p8ebdIIykyqSUKfNJJCgllDJBY_AlPZJJEfBIxAq8dy-NFCc89b3QEzxnPPOzQDDyGG0U00I9RZgTn-QkFyGNfMq4lIxk4AX7eQixc65IB72pWjC5sAIriQ5ModUT3ep6ndQ4gVaHA0371keJ8kxnJXKWfB3RZO8H978NPn9IdjpoawWA-oRAi89xGnfQqwqRBBpYz5ABr6eLGVwuJISG8FB4zRGcsthjLIDHeWKxbJ7aceLZ2j3P0d2mY7xAG_NyoV6CTzuXW45_fwBeP6Gg
link.rule.ids 315,783,787,27936,27937
linkProvider Walter de Gruyter
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+free+light+chains%3A+diagnostic+and+prognostic+value+in+multiple+myeloma&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Sthaneshwar%2C+Pavai&rft.au=Nadarajan%2C+Veerasekaran&rft.au=Maniam%2C+Jayaranee+A+S&rft.au=Nordin%2C+Nani&rft.date=2009-09-01&rft.eissn=1437-4331&rft.volume=47&rft.issue=9&rft.spage=1101&rft_id=info:doi/10.1515%2FCCLM.2009.260&rft_id=info%3Apmid%2F19728852&rft.externalDocID=19728852
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon